Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 2/3 1

Status

Recruiting 3

Sponsor Class

OTHER 2OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 1Gynecologic 1Genitourinary 1

Conditions

Prostate CA 1Ovarian Neoplasms 1Lymphoma, Follicular 1Cognitive Dysfunction 1Alzheimer Disease 1

Interventions

pembrolizumab 551Specimen Handling 465Carboplatin 441Magnetic Resonance Spectroscopy 430Cyclophosphamide 412Cisplatin 397Radiotherapy 313Gemcitabine 309Bevacizumab 307Paclitaxel 294Biopsy 261Drug Therapy 249Capecitabine 242Oxaliplatin 239fludarabine 237Nivolumab 224venetoclax 219Injections 213Docetaxel 205Fluorouracil 203Dexamethasone 187Radiosurgery 172Rituximab 158Pemetrexed 153Standard of Care 146durvalumab 143Leucovorin 139atezolizumab 138toripalimab 134tislelizumab 134

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Interventional × fasudil × Clear all
NCT06362707 2026-05-04

FEAD

Helse Stavanger HF

Phase 2 Recruiting
200 enrolled
Lymphoid

Alzheimer Disease, Lymphoma, Follicular, Cognitive Dysfunction

NCT06861192 2025-11-18

Clinical Study of Fasudil Hydrochloride and PD1 Inhibitor Combined With Androgen Deprivation in Neoadjuvant Therapy of Prostate Cancer

Zhongda Hospital

Phase 2/3 Recruiting
83 enrolled
Genitourinary

Prostate CA

NCT06890858 2025-03-24

A Clinical Study on Fasudil Hydrochloride for Treatment of Gene-Specific Ovarian Cancer

Zhejiang Provincial People's Hospital

Phase 2 Recruiting
20 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡